Certara, Inc. Stock Price, News & Analysis

Certara has appointed Nancy Killefer and Cynthia Collins to its board of directors, effective August 1, 2021, increasing the board to eleven members. Killefer brings over 30 years of executive experience in pharmaceuticals and healthcare, previously serving as a director at McKinsey & Company. Collins, with over 40 years in biotechnology, was CEO at Editas Medicine, where she led significant advancements in gene editing. Both directors aim to leverage their expertise to enhance Certara's drug discovery and development processes.

Certara, Inc. (Nasdaq: CERT) will announce its second quarter 2021 financial results on August 5, 2021, post-market. A conference call with management is scheduled for 5:00 p.m. ET to discuss these results. Investors can join by dialing (833) 360-0946 domestically or (914) 987-7661 internationally, using Conference ID: 2728807. An archived webcast will also be available on the Certara website. Certara specializes in biosimulation technology, assisting over 1,650 clients, which include biopharmaceutical companies and regulatory agencies worldwide.

Certara has appointed Nicolette D. Sherman as Chief Human Resources Officer, bringing over 20 years of HR experience in the biopharmaceutical sector. Previously, she was CHRO at Oyster Point Pharma, where she developed HR strategies for a newly public biotech. Her tenure at Sanofi included roles as Vice President of North American HR Operations and Global Leadership Development. CEO William F. Feehery expressed confidence in Sherman's ability to enhance Certara's capabilities and corporate values, further aligning with the company's mission to transform drug development.

Certara has launched an upgraded version of its BaseCase software, aimed at enhancing the market potential for biopharmaceutical and medical device companies. The new capabilities, which include Data Connect for real-time data updates, aim to improve communications regarding product value. The software is currently utilized in over 60 countries by more than 30,000 users, including leading global firms. This development reflects a strategic move to strengthen Certara’s position in the value-based healthcare sector, providing tools for effective market access and medical affairs.

Certara announced the renewal of its licenses for biosimulation software by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the eighth consecutive year. The PMDA has utilized Certara’s Simcyp™ and Phoenix™ software since 2014. These tools aid in drug development by optimizing dosing regimens and predicting interactions. Certara collaborates with over 130 biopharmaceutical firms in Japan, including the top 10 by R&D expenditure. The continued adoption of biosimulation supports the development of therapies for challenging diseases.

Certara has appointed Carol Gallagher, Pharm.D., to its board of directors, enhancing its governance with her 30+ years of drug development and commercial leadership experience.

Previously a CEO and venture partner, Dr. Gallagher has a notable background in biopharmaceuticals, including her role in developing the cancer drug ZYDELIG. Her experience spans companies like Eli Lilly and Amgen.

Dr. Gallagher's addition is expected to contribute to Certara's mission to accelerate drug development through its biosimulation software, supporting over 1,650 global clients.

Certara, Inc. (Nasdaq: CERT) announced participation in upcoming virtual investor conferences featuring CEO William Feehery and CFO Andrew Schemick. They will speak at William Blair's 41st Annual Growth Stock Conference on June 1 at 11:40 a.m. ET and the Jefferies Virtual Healthcare Conference on June 4 at 10:00 a.m. ET. Live webcasts will be available on Certara's investor relations website and can be replayed for 90 days. Certara specializes in biosimulation software to enhance drug discovery and development for over 1,650 global clients.

Certara has launched new versions of its Immunogenicity and Immuno-oncology Quantitative Systems Pharmacology (QSP) Simulators to tackle challenges in developing biologics and cancer therapies. The updates enhance the simulators' capabilities, allowing for better predictions of clinical outcomes and the testing of therapy combinations. Certara's tools are now critical in regulatory submissions, highlighting the growing importance of QSP in pharmaceutical R&D. The simulators have successfully predicted outcomes for various cancer treatment scenarios, including solid tumors and blood cancers.

Certara reported Q1 fiscal 2021 results with revenue of $66.7 million, a 16% increase from Q1 2020. Net income rose to $1.1 million, with adjusted EBITDA climbing 20% to $23.9 million. The company updated its full-year guidance, projecting revenue between $277 million and $285 million, and adjusted EBITDA of $100 million to $102 million. First quarter bookings grew 34% year-over-year, indicating strong demand for its biosimulation platform.